These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22169807)

  • 1. Orthopaedics: Structural support.
    Berglund J
    Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of bortezomib on bone health in myeloma: a review of current evidence.
    Zangari M; Terpos E; Zhan F; Tricot G
    Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone building with bortezomib.
    Roodman GD
    J Clin Invest; 2008 Feb; 118(2):462-4. PubMed ID: 18219395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
    Wang Y; Lin B
    Bone; 2013 Jul; 55(1):132-49. PubMed ID: 23416846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Terpos E
    Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
    [No Abstract]   [Full Text] [Related]  

  • 11. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Supportive care in multiple myeloma for continuing anti-myeloma therapies].
    Shibayama H
    Rinsho Ketsueki; 2014 Oct; 55(10):1999-2004. PubMed ID: 25297765
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T; Yamasaki R; Omura H; Hino N
    Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
    Nakamura S; Miki H; Kido S; Nakano A; Hiasa M; Oda A; Amou H; Watanabe K; Harada T; Fujii S; Takeuchi K; Kagawa K; Ozaki S; Matsumoto T; Abe M
    Int J Hematol; 2013 Jul; 98(1):66-73. PubMed ID: 23708974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.